NephroGenex Announces Data On Acute Kidney Injury At National Kidney Foundation 2015 Spring Clinical Meetings

DALLAS--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced positive results on preclinical studies that evaluate Pyridorin^® as a treatment for acute kidney injury. The data are being presented today at the National Kidney Foundation’s 2015 Spring Clinical Meetings.

“Pyridorin Treatment in Ischemia-Reperfusion Model of AKI”

Pyridorin is a novel compound shown to target and reduce pathogenic oxidative chemistries that emerge in kidney disease. Oral Pyridorin is being evaluated in a pivotal Phase 3 program in diabetic nephropathy.

In the poster session, “Pyridorin Treatment in Ischemia-Reperfusion Model of AKI,” researchers reported on a preclinical model of hospital-acquired acute kidney injury (AKI), a major cause of morbidity, extended hospitalizations and increased medical costs. AKI can occur from a decreased renal reperfusion during surgery, contrast-dye infusion, and anti-cancer therapies. The AKI that results from these procedures is accompanied by an increase in pathogenic oxidative chemistries which likely contributes to the kidney tissue damage and reduced renal function that develops in this indication. Pyridorin scavenges and inhibits pathogenic oxidative chemistries, and therefore could be a promising treatment for AKI.

The study showed that treatment with Pyridorin significantly reduced the severity of acute kidney injury in a model of ischemia reperfusion, which emulates the AKI that can result following cardiopulmonary bypass surgery. Mice were administered doses of Pyridorin prior to the surgically-induced AKI. Pyridorin treatment was shown to significantly reduce the level of kidney injury, enhance renal function recovery, and reduce post-injury fibrosis. Treatment with a higher dose of Pyridorin was shown to be even more beneficial.

“These are exciting early results with Pyridorin in this important indication,” commented Chief Executive Officer Pierre Legault. “We’re in discussion with the U.S. FDA regarding design of a clinical program in acute kidney injury, and anticipate initiating an AKI Phase 1 study during second half of 2015.”

Also at the meeting, the Company presented PIONEER, the ongoing pivotal Phase 3 trial with Pyridorin in diabetic nephropathy. In a poster session, “Design of a Phase 3 Clinical Trial in Type 2 Diabetic Nephropathy with Pyridoxamine dihydrochloride (Pyridorin),” lessons from previous studies in diabetic nephropathy were discussed, along with the use of a novel renal endpoint that is being used as the primary approvable endpoint. A Special Protocol Assessment (SPA) has been granted to this program by the U.S. FDA.

About Pyridorin^®

Pyridorin inhibits pathogenic oxidative chemistries, which are collectively elevated in diabetic patients and induce pathological changes implicated in the development of diabetic nephropathy. Pyridorin inhibits a broad range of these chemistries which we believe accounts for its effectiveness in slowing the progression of nephropathy in diabetic patients as shown in our Phase 2 studies. Our lead drug candidate was also found to be safe and well tolerated in these same studies.

About NephroGenex, Inc.

NephroGenex (Nasdaq: NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.

Cautionary Note on Forward-Looking Statements

This press release contains certain statements that are, or may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements regarding the outlook for our future business and financial performance. Forward-looking statements are based on our current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from those in the forward-looking statements due to global political, economic, business, competitive, market, regulatory and other factors and risks, including the items identified under "Part I—Item 1A—Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission ("SEC") on March 24, 2015, as well as in other filings that we may make with the SEC in the future. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we do not undertake and specifically disclaim any obligation to update any forward-looking statements.